{"nctId":"NCT00758043","briefTitle":"A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response","startDateStruct":{"date":"2008-10","type":"ACTUAL"},"conditions":["Hepatitis C"],"count":540,"armGroups":[{"label":"T12PR24 (eRVR+)","type":"EXPERIMENTAL","interventionNames":["Drug: telaprevir","Drug: ribavirin","Biological: peginterferon alfa-2a"]},{"label":"T12PR48 (eRVR+)","type":"EXPERIMENTAL","interventionNames":["Drug: telaprevir","Drug: ribavirin","Biological: peginterferon alfa-2a"]},{"label":"T12PR48 (eRVR-)","type":"EXPERIMENTAL","interventionNames":["Drug: telaprevir","Drug: ribavirin","Biological: peginterferon alfa-2a"]},{"label":"Other","type":"EXPERIMENTAL","interventionNames":["Drug: telaprevir","Drug: ribavirin","Biological: peginterferon alfa-2a"]}],"interventions":[{"name":"telaprevir","otherNames":["VX-950"]},{"name":"ribavirin","otherNames":["Copegus"]},{"name":"peginterferon alfa-2a","otherNames":["Pegasys"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C\n* Male and female subjects, 18 to 70 years of age, inclusive\n* Genotype 1, chronic hepatitis C with detectable HCV RNA.\n* Screening laboratory values, tests, and physical exam within acceptable ranges\n* Able and willing to follow contraception requirements\n* Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions.\n\nExclusion Criteria:\n\n* Subject has any contraindications to Pegasys® or Copegus® therapy\n* Evidence of hepatic decompensation in cirrhotic subjects\n* History of organ transplant\n* History of, or any current medical condition which could impact the safety of the subject in participation in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)","description":"SVR24planned was used to measure the primary outcome. SVR24 planned is defined as undetectable HCV RNA levels at the end of treatment (EOT) visit and at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA levels in between those visits. All plasma HCV RNA levels were assessed using the Roche TaqMan HCV RNA assay (Version 2.0, lower limit of quantification \\[LLOQ\\] of 25 IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"76","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Have Undetectable HCV RNA at Week 72","description":"SVR at Week 72 is defined as achieved SVR24planned and undetectable HCV RNA at Week 72 without any confirmed detectable HCV RNA levels in between those visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"76","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12","description":"Extended rapid viral response is defined undetectable HCV RNA levels at Week 4 and Week 12 (on treatment).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"159","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment","description":"SVR12 is defined as undetectable HCV RNA levels 12 weeks after the last planned dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"154","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Randomized Subjects Who Relapse","description":"Proportion of randomized subjects who relapsed was defined as the number of subjects who completed treatment, had undetectable HCV RNA at end of treatment (EOT; Week 24 or Week 48 respectively), and became HCV RNA detectable during antiviral follow-up (24 weeks after EOT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Enrolled Subjects Who Relapse","description":"Proportion of enrolled subjects who relapsed was defined as the number of subjects who had undetectable HCV RNA at the EOT, and became HCV RNA detectable during antiviral follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed by Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"160","spread":null},{"groupId":"OG002","value":"117","spread":null},{"groupId":"OG003","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":162},"commonTop":["FATIGUE","PRURITUS","NAUSEA","ANAEMIA","HEADACHE"]}}}